Neuphoria Therapeutics Inc.
NEUP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $26,481 | $11,523 | $1,347,908 | $802,660 |
| - Cash | $13,650 | $14,210,745 | $17,045 | $4,345 |
| + Debt | $85 | $116,314 | $172 | $199 |
| Enterprise Value | $12,917 | -$14,082,908 | $1,331,035 | $798,515 |
| Revenue | $0 | -$15,663 | $23,874 | $1,071 |
| % Growth | 100% | -165.6% | 2,130.1% | – |
| Gross Profit | -$251 | -$15,332 | $23,611 | $0 |
| % Margin | – | 97.9% | 98.9% | 0% |
| EBITDA | -$14,789 | -$846,807 | $18,059 | -$3,121 |
| % Margin | – | 5,406.5% | 75.6% | -291.5% |
| Net Income | -$14,988 | -$378,146 | $17,925 | -$3,139 |
| % Margin | – | 2,414.3% | 75.1% | -293.2% |
| EPS Diluted | -4.41 | -6.77 | 6.55 | -0.008 |
| % Growth | 34.9% | -203.4% | 79,015.7% | – |
| Operating Cash Flow | -$3,795 | $73,567 | $11,453 | -$3,358 |
| Capital Expenditures | -$0 | -$0 | $0 | $0 |
| Free Cash Flow | -$3,795 | $73,567 | $11,453 | -$3,358 |